Literature DB >> 7127279

Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro.

S E Shackney, S S Ford, S J Occhipinti, P S Ritch, R Riccardi, B W Erickson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7127279

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.

Authors:  Ronald Dubowy; Michael Graham; Nasrollah Hakami; Morris Kletzel; Donald Mahoney; Edward Newman; Yaddanapudi Ravindranath; Bruce Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2008-05       Impact factor: 1.289

2.  Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.

Authors:  M Higashigawa; D C Cao; K Matsui; S Yamada; H Kakitou; Y Kagawa; H Inamochi; M Ido; M Sakurai
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Synchronisation by hydroxyurea does not affect the sensitivity of CEM-C7 lymphoblasts to glucocorticoids.

Authors:  F Maehira; R M Gledhill; A J Edwards; M R Norman
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.